Synthesis Theta
The recipe for efficiency by Universal Pack
The remote installation of a complete packaging line for 4-side-seal sachets has just ended. The pharmaceutical multinational company chose Universal Pack mainly for the high output in terms of cartons/minute, the possibility of compacting the sachets stack with ad hoc systems, the maximum flexibility in formats and reduced blueprint as opposed to competitors’ offer.
The Project
The collaboration between the multinational company and Universal Pack starts with a project concerning the making of a complete packaging line for producing 4-side-seal sachets and automatically inserting them in pre-glued cartons.
The need of the buyer was to adopt a technological solution that would allow maximum production flexibility, high output and compliance with pharmaceutical market requirements, in one solution.
Universal Pack’s answer has satisfied all the specific requests and is structured in the following areas:
The machine speed for 4-side-seal Theta: this vertical machine model allows to reach horizontal machines output, while reducing footprint to a large extent and keeping greater flexibility.
Another key factor in the choice is the compact footprint of the whole line proposed by Universal Pack compared to the equivalent offer by other market players.
The quality in terms of sachets endurance, product integrity and aesthetic beauty produced by Theta machine also affected the decision. The high quality is made possible by a new horizontal sealing concept and a specific liquid cooling system for the sealing parts, avoiding film and product stress during dosing.
Total flexibility in sachet and carton size: this is a key factor especially for contracting companies and companies managing several production batches.
Another reason not to underestimate is the possibility to compact the stacks of sachets before transferring them to the cartoning machine: this process allows to gain greater stability and insert more sachets with equal carton size.
In addition, complying with the goal of operations simplification, adjustments and formats change take place without the need for extra tools.
In order to guarantee the highest precision at any output, the packaging line was equipped with multilane checkweigher, thousandth load cells with direct feedback to the single lanes of the dosing unit. There is also a station for the manual reintegration of rejected sachets.
The extractable dosing system can be placed at ergonomic height to facilitate cleaning operations and format change.
To reduce operational costs while keeping maximum efficiency, it was agreed to provide a completely customized assistance and maintenance plan, including training, on site and remote assistance, predictive maintenance, 4.0.
Remote equipment installation.
10 Advantages of the Project:
• Output speed
• Compact blueprint
• Sachet quality
• Total flexibility in size
• Tool-free adjustments and format change
• Carton volume minimization
• Multilane checkweigher
• Extractable dosing unit
• Operational costs minimization
• Remote plant installation
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...